DEA Sets New Import, Export Restrictions for Mesocarb
The Drug Enforcement Administration is listing mesocarb, a substance with stimulating properties marketed in Russia for treatment of attention deficit hyperactivity disorder that has no approved medical use and no known therapeutic application in the U.S., under Schedule I of…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
the Controlled Substances Act, it said in a notice published Nov. 22. “This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle mesocarb," DEA said. The listing takes effect Dec. 22.